Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
NASDAQ:EVAX
Price:
3.25
USD
-3.56%
Market Closed
Market Cap:
$20.5m
Relative Value
The Relative Value of one
EVAX
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 3.25 USD,
Evaxion Biotech A/S
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EVAX Relative Value
HIDDEN
Multiples Across Competitors
EVAX Competitors Multiples
Evaxion Biotech A/S Competitors
Evaxion Biotech A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
20.5m USD | 2.7 | -3.8 | -1.8 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.7B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD | 10.5 | 31.9 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
71.1B AUD | 3.2 | 16.7 | 11.5 | 14.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 11.4 | 36.5 | 39.7 | 40.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
